AstraZeneca's treatment Truqap has received backing from an FDA advisory committee for use in prostate cancer. However, reports on the outcome of the meeting are not uniform, with some indicating a positive result and others suggesting uncertainty or mixed opinions from advisors. The company's breast cancer treatment, on the other hand, appears to have faced a negative response from the advisory committee.